Genetic testing for haemochromatosis in patients with chondrocalcinosis

A E Timms, R Sathananthan, L Bradbury, N A Athanasou, M A Brown

Hereditary haemochromatosis (HH) is one of the most common inherited diseases, affecting about 300 people of northern European descent. It affects iron handling and if untreated can lead to cirrhosis of the liver, hepatocellular carcinoma, diabetes mellitus, cardiomyopathy, and other conditions resulting in premature death. Three distinct genetic subsets of haemochromatosis have been characterised so far. Type 2 HH has been mapped to chromosome 1q (HFE2), is primarily involved with juvenile haemochromatosis, and has not been related to the more common later onset disease. Type 3 is associated with mutations; Camaschella et al. identified a Tyr to stop signal substitution at codon 282 of the transferrin receptor-2 (TFR2) gene in two Sicilian families and linkage analysis subsequently established a locus at chromosome 7q22 (HFE3). Recently, two more genes involved in iron metabolism have been linked to HH. A mutation within the gene SLC11A3 (solute carrier family 11 A3) was found in all affected members of a large Dutch family. A point mutation of the iron response element motif of H-ferritin mRNA has also been reported to increase cellular iron uptake in a Japanese family. However, by far the most common form is type 1 HH, which is caused by mutations of the HFE gene, and is mapped to 6p21.3. Over 80% of patients with HH are homozygous for a mutation at codon 282, which results in a Cys to Tyr substitution that inhibits HFE/β2-microglobulin binding. A second mutation within the gene at codon 63 (His to Asp) is also associated with HH when inherited in combination with the C282Y mutation, where compound heterozygosity for the two mutations results in increased susceptibility to disease. About 90% of C282Y homozygotes and 38% of H63D/C282Y heterozygotes develop haemochromatosis, and C282Y heterozygotes have also been shown to exhibit minor abnormalities of iron overload. Heterozygosity for the C282Y variant has been associated with porphyria cutanea tarda, coronary heart disease, and type 2 diabetes in some but not all studies.

Chondrocalcinosis is a common rheumatic disease characterised by deposition of calcium salts in the joint cartilage, commonly calcium pyrophosphate dihydrate or calcium hydroxyapatite. Chondrocalcinosis may occur as a complication of various conditions including hyperparathyroidism, haemochromatosis, hypothyroidism, and Wilson’s disease; between 30% and 50% of patients with haemochromatosis also have chondrocalcinosis. Previous studies examining the frequency of haemochromatosis in chondrocalcinosis have not used genetic screening. The aim of this study was to determine the frequency of genetic haemochromatosis in chondrocalcinosis and to assess the risk of disease in heterozygotes for the C282Y polymorphism.

PATIENTS AND METHODS

Patients

A total of 128 patients (70 male and 58 female) were recruited from the Nuffield Orthopaedic Centre. Patients were recruited because of either radiographic chondrocalcinosis (at least bicompartamental knee disease or involvement of joints other than the knee (82 (64%) patients)) or calcium pyrophosphate dihydrate pseudogout (46 (36%) patients). Ages ranged from 28 to 89 years, mean 64.7 years. Patients were recruited irrespective of whether they had previously been screened for metabolic diseases associated with haemochromatosis. None of the patients had previously been diagnosed as having iron overload.

Laboratory and statistical methods

A polymerase chain reaction using sequence specific primers (PCR/SSP) was used to identify alleles at both polymorphisms within codons 63 and 282 (fig 1). Results at codon 282 were confirmed by PCR using restriction fragment length polymorphism (PCR/RFLP). Historical white controls of European descent were used for comparison.

Abbreviations: HH, hereditary haemochromatosis; PCR/RFLP, polymerase chain reaction using restriction fragment length polymorphism; PCR/SSP, polymerase chain reaction using sequence specific primers;
were genotyped as part of a large community survey and are therefore not significantly affected by ascertainment bias. This problem may lead to underestimation of haemochromatosis gene frequencies when exclusion of diagnosed cases may inadvertently have occurred.

Relative risk of genotypes was determined by standard methods.

## RESULTS

Results for both polymorphisms in comparison with the historical white controls are shown in table 1. We identified two previously undiagnosed C282Y homozygotes (1.6%) in patients compared with 16 of 3011 controls (0.5%). This represents a significant overrepresentation of C282Y homozygotes (relative risk 3.4, p=0.037). We also identified four C282Y/H63D compound heterozygotes (3.1%), a similar proportion to the normal control population (2.2%). There was also no significant difference in the number of C282Y heterozygotes (12.5% in the patient group v 11.9% in the control group). Genotyping results of codon 282 were consistent with PCR/SSP and PCR/RFLP in all 128 patients.

The genotyping cost for each patient was £1, representing the consumable costs for DNA extraction, PCR/RFLP, and PCR/SSP; thus in this subset of patients with chondrocalcinosis the cost for each C282Y homozygote discovered was £64.

## DISCUSSION

This study confirms the association of haemochromatosis caused by homozygosity for the C282Y HFE variant, with significant chondrocalcinosis, as defined by ascertainment criteria for this study. Although haemochromatosis remains an uncommon cause of chondrocalcinosis, it is sufficiently frequent that screening for haemochromatosis is clearly worthwhile in patients with appreciable chondrocalcinosis. However, whether screening patients with less severe chondrocalcinosis is worthwhile is uncertain. Previous studies have shown that patients with haemochromatosis and chondrocalcinosis are younger and more likely to be male than patients with chondrocalcinosis not associated with haemochromatosis. Screening elderly patients with mild chondrocalcinosis may not therefore be as worthwhile.

We found no association of chondrocalcinosis with genotypes causing less severe concentrations of iron overload, such as C282Y/wild-type and C282Y/H63D heterozygote genotypes. This indicates that unlike the situation in porphyria cutanea tarda, mild degrees of iron overload are not sufficient to cause chondrocalcinosis. The study had 80% power to detect an association (for p<0.05, one tailed) with C282Y heterozygotes with an odds ratio of less than 1.9, and an association with C282Y/H63D compound heterozygotes with an odds ratio of less than 3.2. Thus associations of smaller magnitude may not have been found in this study.

Previous modelling of cost effectiveness of screening for haemochromatosis has suggested that screening is cost effective if the prevalence of disease in the screened population was equal to 3/1000, the positive predictive value of the diagnostic test was less than 0.4, and the test cost was less than $12. The positive predictive value of C282Y screening is more than 80%, and the cost of the genetic test in our laboratory is about £1, well within the values required for screening to be cost effective. Although further studies are required to confirm our findings, this study suggests that there is a strong argument for widespread genetic screening for haemochromatosis in patients with appreciable chondrocalcinosis and onset of chondrocalcinosis at an early age.

## Table 1  HFE polymorphism genotypes in patient and historical control populations

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Patients n (%)</th>
<th>Historical controls n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C282Y/C282Y</td>
<td>2(1.6)*</td>
<td>16(0.5)</td>
</tr>
<tr>
<td>C282Y/wild-type</td>
<td>16(13)</td>
<td>359(12)</td>
</tr>
<tr>
<td>C282Y/H63D</td>
<td>4(3.1)</td>
<td>65(2.2)</td>
</tr>
<tr>
<td>Other</td>
<td>110(86)</td>
<td>2636(88)</td>
</tr>
<tr>
<td>Total</td>
<td>128</td>
<td>3011</td>
</tr>
</tbody>
</table>

*Relative risk 3.4, p=0.037.

---

**Authors’ affiliations**

A E Timms, R Sathananthan, L Bradbury, M A Brown, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Headington, Oxford, OX3 7BN, UK

N A Athanasou, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford, OX3 7JD, UK

Correspondence to: Dr M Brown, Spondyloarthritides and Bone Disease Research Group, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Headington, OX3 7BN, UK; mbrown@well.ox.ac.uk

Accepted 25 February 2002
ACKNOWLEDGEMENT
This work was funded by the Arthritis Research Campaign, UK.

REFERENCES
Genetic testing for haemochromatosis in patients with chondrocalcinosis

A E Timms, R Sathananthan, L Bradbury, N A Athanasou and M A Brown

Ann Rheum Dis 2002 61: 745-747
doi: 10.1136/ard.61.8.745

Updated information and services can be found at:
http://ard.bmj.com/content/61/8/745

These include:

References
This article cites 19 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/61/8/745#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/62/2/192.full.pdf

Topic Collections
Articles on similar topics can be found in the following collections

Degenerative joint disease (4641)
Musculoskeletal syndromes (4951)
Epidemiology (1387)
Genetics (968)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
CORRECTION


The authors regret that owing to an administrative oversight B P Wordsworth was omitted as one of the authors of this paper. The correct listing of authors is as follows: A E Timms, R Sathananthan, L Bradbury; N A Athanasou, B P Wordsworth, MA Brown.

FORTHCOMING EVENTS

Eleventh Intensive Applied Epidemiology Course for Rheumatologists
24–28 Feb 2003; ARC Epidemiology Unit, Manchester
No previous experience in epidemiology is required. The course is residential and limited to 25 places
Contact: Ms Lisa Mc Clair, ARC Epidemiology Unit, Manchester, Oxford Road, Manchester M13 9PT, UK
Tel: +44 (0)161 275 5993 Fax: +44 (0)161 275 5043 Email: Lisa@fs1.ser.man.ac.uk

23rd European Workshop for Rheumatology Research
27 Feb–2 Mar 2003; Marseille, France

4th Annual European Congress of Rheumatology AGM
1–4 April 2003; Manchester, UK
Contact: Julia Kermode
Tel: +44 (0) 20 7242 3313 Fax: +44 (0) 20 7242 3277 Email: julia@rheumatology.org.uk Website: www.rheumatology.org.uk

7th EULAR Sonography Course
9–12 October; Rome, Italy
An introductory and practical course on musculoskeletal ultrasonography
Scientific secretariat: Professor Guido Valesini
Email: annamaria.iagrocco@uniroma1.it
Contact: Organising secretariat: Michela Civelli, EDRA Spa, Medical Publishing and News Media, Viale Monza, 133–20125, Milan, Italy
Tel: +39 (0)2 281 72300 Fax: +39 (0)2 281 72399 Email: edracongressi@adsmedigroup.com

OARSI World Congress on Osteoarthritis
12–15 October 2003; Berlin, Germany
Tel: +49 (0) 30 268 3330 Fax: +49 (0) 30 268 3331 Email: oarsi@oarsi.org Website: www.oarsi.org

Fourth International Symposium on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
14–17 November 2003; Nice, France
Contact: Organisation Secretariat, YP Communication, 108 boulevard G Kleyer, 4000 Liège, Belgium
Tel: +32 (4) 254 12 25 Fax: +32 (4) 254 12 90 Email: yoland@piettecommunication.com Website: http://nice.piettecommunication.com

Future EULAR congresses
9–12 June 2004; EULAR 2004; Berlin, Germany
8–11 June 2005; EULAR 2005; Vienna, Austria
21–24 June 2006; EULAR 2006; Amsterdam, The Netherlands

Future ACR meetings
24–28 October 2003; 67th Annual Scientific Meeting; Orlando, Florida
16–21 October 2004; 68th Annual Scientific Meeting; San Antonio, Texas